Annovis Bio, Inc

At Annovis Bio, Inc., we are pioneering a novel approach to fighting chronic and acute neurodegeneration, offering new hope against the largest unmet need of our aging population - Alzheimers and Parkinsons diseases. Our diverse pipeline also targets such neurodegenerative conditions as traumatic brain injury (TBI), stroke, Down Syndrome, Huntington disease, and mental illnesses. Our lead compound, buntanetap, is a small, once-daily, orally administered, brain-penetrant inhibitor of neurotoxic proteins. The biological activity of buntanetap has been evaluated in 19 animal studies conducted in leading institutions such as the Karolinska Institute, Columbia University, and Harvard University. We have also conducted seven...

Neurodegeneration,alzheimer’s,parkinson’s,alzheimer’s in down syndrome,axonal transport,traumatic brain injury,app,tau,asyn,neurotoxic proteins,app/ab (app),tau/phospho-tau,and a-synuclein (a-syn)

Annovis bio, inc operates in the Biotechnology research industry.

Annovis bio, inc's revenue is < 1m

Annovis bio, inc has 11 - 50 employees.